KR101554258B1 - 뇌혈관 연축의 예방을 위한 약물 전달 시스템 - Google Patents

뇌혈관 연축의 예방을 위한 약물 전달 시스템 Download PDF

Info

Publication number
KR101554258B1
KR101554258B1 KR1020157012919A KR20157012919A KR101554258B1 KR 101554258 B1 KR101554258 B1 KR 101554258B1 KR 1020157012919 A KR1020157012919 A KR 1020157012919A KR 20157012919 A KR20157012919 A KR 20157012919A KR 101554258 B1 KR101554258 B1 KR 101554258B1
Authority
KR
South Korea
Prior art keywords
calcium channel
vasospasm
cerebral
pharmaceutical composition
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157012919A
Other languages
English (en)
Korean (ko)
Other versions
KR20150061031A (ko
Inventor
알. 로치 맥도날드
브라이언 로이트너
Original Assignee
알. 로치 맥도날드
브라이언 로이트너
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알. 로치 맥도날드, 브라이언 로이트너 filed Critical 알. 로치 맥도날드
Publication of KR20150061031A publication Critical patent/KR20150061031A/ko
Application granted granted Critical
Publication of KR101554258B1 publication Critical patent/KR101554258B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157012919A 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템 Expired - Fee Related KR101554258B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94312407P 2007-06-11 2007-06-11
US60/943,124 2007-06-11
US97690207P 2007-10-29 2007-10-29
US60/976,902 2007-10-29
PCT/US2008/066576 WO2008154585A1 (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107000554A Division KR101554250B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Publications (2)

Publication Number Publication Date
KR20150061031A KR20150061031A (ko) 2015-06-03
KR101554258B1 true KR101554258B1 (ko) 2015-09-18

Family

ID=40096090

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020107000554A Expired - Fee Related KR101554250B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템
KR1020157012919A Expired - Fee Related KR101554258B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템
KR1020147036026A Expired - Fee Related KR101607244B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020107000554A Expired - Fee Related KR101554250B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147036026A Expired - Fee Related KR101607244B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Country Status (10)

Country Link
US (2) US8303974B2 (enExample)
EP (1) EP2164497B1 (enExample)
JP (1) JP5576790B2 (enExample)
KR (3) KR101554250B1 (enExample)
CN (3) CN101873858B (enExample)
AU (1) AU2008261668C1 (enExample)
CA (1) CA2690600C (enExample)
IL (1) IL202647A (enExample)
NZ (2) NZ581836A (enExample)
WO (1) WO2008154585A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101554250B1 (ko) * 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템
US10092524B2 (en) * 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
CN102834104A (zh) * 2010-02-22 2012-12-19 优势医疗公司 治疗脑的出血性病状的方法和组合物
EP2627173B2 (en) 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipine emulsion formulations containing antimicrobial agents
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN107115270A (zh) * 2011-02-11 2017-09-01 优势医疗公司 用于改善患有蛛网膜下腔出血的人的预后的组合物和方法
EP2694133B1 (en) * 2011-04-05 2018-05-23 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
CN102416013A (zh) * 2011-12-30 2012-04-18 湖南九典制药有限公司 西尼地平的新用途
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
US9655999B2 (en) 2013-03-12 2017-05-23 Carnegie Mellon University Coated vaso-occlusive device for treatment of aneurysms
CN103211812A (zh) * 2013-04-02 2013-07-24 苏州大学附属第一医院 Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用
US10403395B2 (en) * 2013-10-14 2019-09-03 SecondOpinionExpert, Inc. Method and apparatus for generating objective medical second opinion
CN107427666B (zh) * 2015-01-30 2022-11-04 加利福尼亚大学校董 脊髓软膜下基因递送系统
GB2556500A (en) * 2015-05-29 2018-05-30 Edge Therapeutics Inc Compositions and methods for reducing visual loss
WO2017024032A2 (en) * 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
IL271908B2 (en) 2017-07-11 2024-02-01 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
US10435434B2 (en) 2018-01-12 2019-10-08 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US20200163947A1 (en) * 2018-11-02 2020-05-28 Nortic Holdings Inc. Methods of treatment using nimodipine parenteral formulations
US20200315547A1 (en) * 2019-04-02 2020-10-08 Tencent America LLC Vertebral artery dissection risk evaluation method, computer device, and storage medium
US11103142B2 (en) * 2019-04-02 2021-08-31 Tencent America LLC System and method for predicting vertebral artery dissection
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
JPH09507487A (ja) 1994-01-05 1997-07-29 アーキュール，インコーポレーテッド 選ばれた性質を有するアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造
US5712171A (en) * 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
ATE314843T1 (de) 1996-03-12 2006-02-15 Pg Txl Co Lp Wasserlösliche paclitaxel-prodrogen
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6284283B1 (en) * 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) * 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
EP2444069B1 (en) * 2003-07-23 2019-06-05 Evonik Corporation Controlled release compositions
CN1480128A (zh) * 2003-08-06 2004-03-10 北京扬新科技有限公司 一种透明、隐形的外用药物制剂
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7829527B2 (en) * 2005-02-02 2010-11-09 University Of Vermont And State Agricultural College Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
KR101554250B1 (ko) * 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Life Sciences, Vol. 52, No. 9, pp. 825-834, 1993.
Life Sciences, Vol. 62, No. 13, pp. 191-197, 1998.
Stroke, Vol. 38, No. 2, pp. 330-336, 2007.02.01.

Also Published As

Publication number Publication date
KR101554250B1 (ko) 2015-09-18
KR20100055385A (ko) 2010-05-26
NZ599430A (en) 2014-03-28
AU2008261668B2 (en) 2013-08-29
EP2164497B1 (en) 2018-08-15
KR20150015514A (ko) 2015-02-10
EP2164497A4 (en) 2013-05-29
IL202647A (en) 2015-02-26
WO2008154585A1 (en) 2008-12-18
CN105963242A (zh) 2016-09-28
IL202647A0 (en) 2010-06-30
NZ581836A (en) 2012-07-27
AU2008261668C1 (en) 2014-01-16
CN101873858B (zh) 2016-05-25
JP5576790B2 (ja) 2014-08-20
JP2010529205A (ja) 2010-08-26
EP2164497A1 (en) 2010-03-24
US20130022660A1 (en) 2013-01-24
US20080305147A1 (en) 2008-12-11
KR101607244B1 (ko) 2016-03-30
KR20150061031A (ko) 2015-06-03
CN101873858A (zh) 2010-10-27
AU2008261668A1 (en) 2008-12-18
CA2690600C (en) 2016-10-11
CN105055300A (zh) 2015-11-18
US8303974B2 (en) 2012-11-06
CA2690600A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
KR101554258B1 (ko) 뇌혈관 연축의 예방을 위한 약물 전달 시스템
RU2606169C2 (ru) Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
JP6146814B2 (ja) クモ膜下出血のヒトの予後を改善する組成物及び方法
AU2016201681B2 (en) A drug delivery system for the prevention of cerebral vasospasm
AU2013203192B2 (en) A drug delivery system for the prevention of cerebral vasospasm
HK1229243A1 (en) A drug delivery system for the prevention of cerebral vasospasm
CA2826890A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
HK1230079A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
NZ613970B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20180828

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

Not in force date: 20190915

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190915

St.27 status event code: N-4-6-H10-H13-oth-PC1903